You are here

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Arizona Oncology Associates, PC - NAHOA
Flagstaff, Arizona, 86001 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically or cytologically confirmed carcinoma of the breast

- Locally advanced breast cancer that is not amenable to curative radiation or surgical
cure and/or metastatic disease appropriate for systemic single cytotoxic chemotherapy

- Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or
BRCA2 mutation from Myriad Genetics or other laboratory approved by the Sponsor

- No more than 3 prior chemotherapy-inclusive regimens for locally advanced and/or
metastatic disease (no limit on prior hormonal therapies or targeted anticancer
therapies such as mechanistic target of rapamycin (mTOR) or CDK4/6 inhibitors,
immune-oncology agents, tyrosine kinase inhibitors, or monoclonal antibodies against
CTL4 or VEGF)

- Prior treatment with a taxane and/or anthracycline in the neoadjuvant, adjuvant,
locally advanced, or metastatic setting unless medically contraindicated

- Have measurable or non-measurable, evaluable disease by the revised response
evaluation criteria in solid tumors (RECIST) v.1.1

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- First-line locally advanced and/or metastatic breast cancer with no prior adjuvant
chemotherapy unless the Investigator determines that one of the 4 cytotoxic
chemotherapy agents in the control arm would otherwise be offered to the subject

- Prior treatment with a PARP inhibitor (not including iniparib)

- Not a candidate for treatment with at least 1 of the treatments of protocol-specific
physician's choice (ie, capecitabine, eribulin, gemcitabine, vinorelbine)

- Subjects who had objective disease progression while receiving platinum chemotherapy
administered for locally advanced or metastatic disease; subjects who received
low-dose platinum therapy administered in combination with radiation therapy are not
excluded

- Subjects who have received platinum in the adjuvant or neoadjuvant setting are
eligible; however, subjects may not have relapsed within 6 months of the last dose of
prior platinum therapy

- Cytotoxic chemotherapy within 14 days before randomization

- Radiation or anti-hormonal therapy or other targeted anticancer therapy within 14 days
before randomization

- HER2 positive breast cancer

- Active inflammatory breast cancer

- CNS metastases

- Exception: Adequately treated brain metastases documented by baseline CT or MRI
scan that has not progressed since previous scans and that does not require
corticosteroids (except prednisone ? 5 mg/day or equivalent) for management of
CNS symptoms. A repeat CT or MRI following the identification of CNS metastases
(obtained at least 2 weeks after definitive therapy) must document adequately
treated brain metastases.

- Subjects with leptomeningeal carcinomatosis are not permitted

- Prior malignancy except for any of the following:

- Prior BRCA-associated cancer as long as there is no current evidence of the
cancer

- Carcinoma in situ or non-melanoma skin cancer

- A cancer diagnosed and definitively treated ? 5 years before randomization with
no subsequent evidence of recurrence

- Known to be human immunodeficiency virus positive

- Known active hepatitis C virus, or known active hepatitis B virus

- Known hypersensitivity to any of the components of talazoparib

NCT01945775
Pfizer
Active, not recruiting
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Neoplasms, Breast Neoplasms
NCT03343054
All Genders
20+
Years
Multiple Sites
Breast Neoplasms, Stomach Neoplasms, Esophagogastric Junction Neoplasm, Non-small-cell Lung Carcinoma
NCT03284723
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now